Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. J of Skin. 2023;7(2):s176. doi:10.25251/skin.7.supp.176